The Phase l trial will evaluate KTX-1001 to treat relapsed or refractory multiple myeloma. Credit: www.scientificanimations.com / commons.wikimedia.org.

K36 Therapeutics has dosed the first patient in a Phase l trial of KTX-1001 for the treatment of relapsed or refractory multiple myeloma (RRMM).

Lead principal investigator of the trial and director of Myeloma Research for SCRI at Tennessee Oncology, Jesus Berdeja, has dosed the patient in Nashville, Tennessee, US.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The Phase l trial is an open-label, dose escalation and expansion study.

It will assess the safety, tolerability, pharmacology, and initial clinical activity of KTX-1001 to prevent the dimethylation of H3K36 in adult RRMM patients.  

In the dose escalation stage or Part A of the trial, patients will be investigated for incidence of dose-limiting toxicities (DLTs) during cycle one (28 days).

See Also:

The KTX-1001 MTD, RP2D, and schedule will also be determined.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

In Part B or the dose expansion stage, patients with translocation t(4;14) or a GOF mutation in MMSET will be included.

They will be given KTX-1001 at the RP2D to further determine the safety and tolerability as well as offer preliminary efficacy data.

The trial plans to include 60 subjects, with an aim to complete the same by October 2025.

K36 Therapeutics CEO Terry Connolly said: “KTX-1001 has not only demonstrated encouraging preclinical activity and a favourable tolerability profile, but it also addresses unmet need for patients who have received other standard of care therapies available to patients suffering from multiple myeloma.

“We look forward to working with all our sites, investigators, and study teams to efficiently enrol our Phase l clinical trial.”